Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 41
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Vet Comp Oncol ; 18(4): 570-579, 2020 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-32072720

RESUMO

MicroRNA-214 (miR-214), a pivotal tumour-suppressive miRNA, is downregulated in canine hemangiosarcoma (HSA) cells. Although these tumour-suppressive miRNAs are potential therapeutic agents, their clinical efficacy may be limited because of their vulnerability to RNase-rich microenvironments and low in vivo transfection rates. We developed synthetic miR-214s with enhanced cytotoxicity, RNase resistance and quantity of miR-214 in/on cells. These synthetic miR-214s were synthesized by various chemical modifications (such as 4'-aminoethyl-2'-fluoro, 2'-fluoro, 2'-O-methyl, phosphorothioate and oligospermine modifications) of the wild-type mature miR-214 sequences. Transfection of HSA cells with synthetic miR-214 (miR-214 5AE) demonstrated significant growth suppressive effect and induced the strongest apoptotic response. Synthetic miR-214s (miR-214 5AE, miR-214 10AE and miR-214 OS) were much more stable than mature miR-214s in foetal bovine serum. Similar to mature miR-214, 5AE and OS suppressed the expression level of COP1 in HSA cells. The quantity of synthetic miR-214s in/on cells was higher than that of mature miR-214. In conclusion, we developed a clinically applicable, synthetic miR-214 5AE that regulates the COP1 protein expression similar to that mediated by mature miR-214. Additionally, miR-214 5AE confers better cytotoxicity, nuclease resistance and transfection rate than mature miR-214. Thus, miR-214 5AE could potentially be a novel miRNA-based chemotherapeutic agent that could improve the prognosis of HSA. Its in vivo effects on canine HSA need to be examined in future.


Assuntos
Antineoplásicos/farmacologia , Doenças do Cão/tratamento farmacológico , Hemangiossarcoma/veterinária , MicroRNAs/farmacologia , Ribonucleases/efeitos dos fármacos , Animais , Linhagem Celular Tumoral , Cães , Regulação para Baixo , Hemangiossarcoma/tratamento farmacológico , Ubiquitina-Proteína Ligases/efeitos dos fármacos
2.
PLoS One ; 14(9): e0223008, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31568482

RESUMO

Nucleases are enzymes that can degrade genomic DNA and RNA that decrease the accuracy of quantitative measures of those nucleic acids. Here, we study conventional heating, standard microwave irradiation, and Lyse-It, a microwave-based lysing technology, for the potential to fragment and inactivate DNA and RNA endonucleases. Lyse-It employs the use of highly focused microwave irradiation to the sample ultimately fragmenting and inactivating RNase A, RNase B, and DNase I. Nuclease size and fragmentation were determined visually and quantitatively by SDS polyacrylamide gel electrophoresis and the mini-gel Agilent 2100 Bioanalyzer system, with a weighted size calculated to depict the wide range of nuclease fragmentation. Enzyme activity assays were conducted, and the rates were calculated to determine the effect of various lysing conditions on each of the nucleases. The results shown in this paper clearly demonstrate that Lyse-It is a rapid and highly efficient way to degrade and inactivate nucleases so that nucleic acids can be retained for down-stream detection.


Assuntos
Desoxirribonuclease I/química , Fragmentos de Peptídeos/análise , Ribonuclease Pancreático/química , Ribonucleases/química , DNA/química , Desoxirribonuclease I/efeitos dos fármacos , Desoxirribonuclease I/efeitos da radiação , Detergentes/farmacologia , Eletroforese em Gel de Poliacrilamida , Temperatura Alta , Hidrólise , Micro-Ondas , Peso Molecular , Proteólise/efeitos dos fármacos , Proteólise/efeitos da radiação , RNA/química , Ribonuclease Pancreático/efeitos dos fármacos , Ribonuclease Pancreático/efeitos da radiação , Ribonucleases/efeitos dos fármacos , Ribonucleases/efeitos da radiação , Soluções
3.
Neurosci Lett ; 686: 33-40, 2018 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-30179651

RESUMO

Monocytechemotactic protein-induced protein 1 (MCPIP1), a newly recognized mRNA endonuclease, can be induced by lipopolysaccharide (LPS) and ischemic attack, then exerts a negative feedback loop against neuroinflammatory injury, but the specific underlying signaling pathway of the induction is unclear. Toll-like receptors (TLRs) and receptor for advanced glycation end products (RAGE) signaling pathways are involved in LPS/ischemia-evoked inflammation. This study aims to explore which receptor signaling is mainly involved in the induction of MCPIP1 by LPS and ischemic attack. BV2 cells and mice were subjected to LPS stimulation or transient middle cerebral artery occlusion (MCAO) to examine the modulation of MCPIP1. Specific inhibitors for TLR4, TLR2 or RAGE were preadministered to explore the mechanisms of MCPIP1 expression. Results showed that MCPIP1 was significantly increased by LPS and ischemic stress both in vitro and in vivo in time and dose dependent manners. Inhibition of TLR4, rather than TLR2 or RAGE, downregulated the LPS/ischemia-induced expression of MCPIP1 and reduced the levels of TLR4, MyD88, phosphorylated-MAPK (p-P38), phosphorylated-IκBα (p-IκBα), as well as the translocation of NF-κB (p65). In conclusion, we firstly demonstrate that TLR4 signaling pathway, not TLR2 or RAGE, predominantly mediates the LPS/ischemia-induced expression of MCPIP1 in microglia.


Assuntos
Isquemia/metabolismo , Microglia/metabolismo , Ribonucleases/metabolismo , Receptor 4 Toll-Like/metabolismo , Animais , Citocinas/metabolismo , Lipopolissacarídeos/farmacologia , Camundongos Endogâmicos C57BL , Microglia/efeitos dos fármacos , Ribonucleases/efeitos dos fármacos , Transdução de Sinais/efeitos dos fármacos , Receptor 4 Toll-Like/efeitos dos fármacos
4.
Neuron ; 94(6): 1056-1070, 2017 Jun 21.
Artigo em Inglês | MEDLINE | ID: mdl-28641106

RESUMO

Multiple neurodegenerative diseases are characterized by single-protein dysfunction and aggregation. Treatment strategies for these diseases have often targeted downstream pathways to ameliorate consequences of protein dysfunction; however, targeting the source of that dysfunction, the affected protein itself, seems most judicious to achieve a highly effective therapeutic outcome. Antisense oligonucleotides (ASOs) are small sequences of DNA able to target RNA transcripts, resulting in reduced or modified protein expression. ASOs are ideal candidates for the treatment of neurodegenerative diseases, given numerous advancements made to their chemical modifications and delivery methods. Successes achieved in both animal models and human clinical trials have proven ASOs both safe and effective. With proper considerations in mind regarding the human applicability of ASOs, we anticipate ongoing in vivo research and clinical trial development of ASOs for the treatment of neurodegenerative diseases.


Assuntos
Doenças Neurodegenerativas/tratamento farmacológico , Oligonucleotídeos Antissenso/uso terapêutico , Animais , Barreira Hematoencefálica/metabolismo , Encéfalo/efeitos dos fármacos , Encéfalo/metabolismo , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Humanos , Injeções Intraventriculares , Injeções Espinhais , Camundongos , Doenças Neurodegenerativas/metabolismo , Oligonucleotídeos Antissenso/farmacologia , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo
5.
Arthritis Rheumatol ; 67(12): 3209-18, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26315540

RESUMO

OBJECTIVE: Systemic lupus erythematosus (SLE) is characterized by the uncontrolled production of inflammatory cytokines, among which type I interferon (IFN) is recognized as a crucial pathogenic factor. The expression of microRNA-146a (miR-146a) is reduced in the white blood cells of SLE patients and accounts for their overactivated inflammatory responses. However, the mechanism of the reduction of miR-146a is still not fully understood. This study was undertaken to test whether the key pathogenic cytokine, type I IFN, is responsible for the dysregulation of miR-146a in SLE. METHODS: Gene and protein expression was measured in all cells by reverse transcription-quantitative polymerase chain reaction, Northern blotting, or Western blotting. In THP-1 cells, expression of monocyte chemotactic protein-induced protein 1 (MCPIP-1) was knocked down with a lentivirus encoding a short hairpin RNA targeting MCPIP1. The cells were pretreated with type I IFN and assessed for gene expression levels of miR-146a. White blood cells from patients with SLE were analyzed for the expression of the IFN-inducible genes MCPIP1 and miR-146a, and the gene expression data were compared for correlation. RESULTS: Pretreatment of THP-1 cells with type I IFN attenuated the induction of miR-146a posttranscriptionally, by down-regulating the expression of pre-miR-146a but not pri-miR-146a or its original unspliced transcript. Expression of MCPIP-1, which was enhanced by type I IFN, was found to be responsible for the inhibition of miR-146a. In white blood cells from patients with SLE, MCPIP1 expression was elevated, and its expression correlated positively with the IFN score and negatively with the miR-146a transcript level. CONCLUSION: Type I IFN inhibits the maturation of miR-146a through the up-regulation of MCPIP-1, and thus contributes to the uncontrolled inflammation and excessive inflammatory gene expression in SLE.


Assuntos
Interferon Tipo I/farmacologia , Lúpus Eritematoso Sistêmico/genética , MicroRNAs/efeitos dos fármacos , Monócitos/efeitos dos fármacos , RNA Mensageiro/efeitos dos fármacos , Ribonucleases/efeitos dos fármacos , Fatores de Transcrição/efeitos dos fármacos , 2',5'-Oligoadenilato Sintetase/genética , 2',5'-Oligoadenilato Sintetase/imunologia , Antígenos de Superfície/genética , Antígenos de Superfície/imunologia , Linhagem Celular , Proteínas Ligadas por GPI/genética , Proteínas Ligadas por GPI/imunologia , Expressão Gênica , Técnicas de Silenciamento de Genes , Humanos , Interferon Tipo I/genética , Interferon Tipo I/imunologia , Leucócitos/imunologia , Lipopolissacarídeos/farmacologia , Lúpus Eritematoso Sistêmico/imunologia , MicroRNAs/genética , MicroRNAs/imunologia , Monócitos/imunologia , Proteínas de Resistência a Myxovirus/genética , Proteínas de Resistência a Myxovirus/imunologia , RNA Mensageiro/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Ribonucleases/genética , Ribonucleases/imunologia , Fatores de Transcrição/genética , Fatores de Transcrição/imunologia , Regulação para Cima/efeitos dos fármacos
6.
Arthritis Rheumatol ; 67(8): 2117-28, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25917063

RESUMO

OBJECTIVE: Enhanced expression of interleukin-6 (IL-6) plays an important role in the pathogenesis of osteoarthritis (OA). Monocyte chemoattractant protein-induced protein 1 (MCPIP-1) is a novel posttranscriptional regulator of IL-6 expression and is targeted by microRNA-9 (miR-9). We investigated the expression of MCPIP-1 in OA cartilage and explored whether targeting of MCPIP-1 by miR-9 contributes to enhanced IL-6 expression in OA. METHODS: Gene and protein expression in IL-1ß-stimulated human OA chondrocytes/cartilage was determined by TaqMan assay and immunoblotting, respectively. Messenger RNA (mRNA) for MCPIP-1 and IL-6 expression at the single-cell level was analyzed using RNAscope. MCPIP-1 protein interaction with IL-6 mRNA was investigated using RNA immunoprecipitation. Transient transfections were used for the small interfering RNA (siRNA)-mediated knockdown and overexpression of MCPIP-1, its RNase-defective mutant miR-9, or antagomir. The role of signaling pathways was evaluated using small-molecule inhibitors. Binding of miR-9 with the "seed sequence" in the 3'-untranslated region of MCPIP-1 mRNA was investigated using a luciferase reporter assay. RESULTS: MCPIP-1 mRNA expression was low, but expression of miR-9 and IL-6 was high, in damaged OA cartilage. In IL-1ß-stimulated OA chondrocytes, the expression of miR-9 and MCPIP-1 was mutually exclusive, and increased expression of miR-9 correlated with reduced MCPIP-1 expression and enhanced IL-6 expression. MCPIP-1 protein directly binds with IL-6 mRNA, and overexpression of wild-type MCPIP-1 destabilized the IL-6 mRNA. MCPIP-1 expression was altered by overexpression or inhibition of miR-9. Transfection with miR-9 mimics inhibited the reporter activity, and mutation of the "seed sequence" abolished the repression of reporter activity. CONCLUSION: These findings implicate miR-9-mediated suppression of MCPIP-1 in the pathogenesis of OA via up-regulation of IL-6 expression in IL-1ß-stimulated human OA chondrocytes.


Assuntos
Cartilagem Articular/metabolismo , Condrócitos/metabolismo , Interleucina-6/genética , MicroRNAs/genética , Osteoartrite do Quadril/genética , RNA Mensageiro/metabolismo , Ribonucleases/genética , Fatores de Transcrição/genética , Idoso , Cartilagem Articular/efeitos dos fármacos , Células Cultivadas , Condrócitos/efeitos dos fármacos , Técnicas de Silenciamento de Genes , Humanos , Imunoprecipitação , Interleucina-1beta/farmacologia , Interleucina-6/metabolismo , MicroRNAs/efeitos dos fármacos , MicroRNAs/metabolismo , Pessoa de Meia-Idade , Osteoartrite do Quadril/metabolismo , RNA Mensageiro/efeitos dos fármacos , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo , Fatores de Transcrição/efeitos dos fármacos , Fatores de Transcrição/metabolismo
7.
Arterioscler Thromb Vasc Biol ; 33(6): 1384-91, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23580143

RESUMO

OBJECTIVE: Patients with rheumatoid arthritis are prone to atherosclerosis. We explored the role of elevated level of monocyte chemotactic protein-1 (MCP-1)-induced protein (MCPIP) in endothelial dysfunction associated with rheumatoid arthritis. APPROACH AND RESULTS: The level of MCP-1 was elevated in sera from mice with collagen-induced arthritis (CIA) and was negatively correlated with endothelium-dependent vessel dilation. Aortas from CIA mice showed increased expression of MCPIP but decreased bioavailability of endothelial NO synthase-derived NO. Administering MCP-1 neutralizing antibody to CIA mice decreased the MCPIP level in aortas and alleviated endothelial dysfunction. In vitro, treating cultured vascular endothelial cells with MCP-1 or sera from CIA mice or rheumatoid arthritis patients increased the expression of MCPIP but inhibited endothelial NO synthase phosphorylation. These detrimental effects were reproduced in endothelial cells overexpressing MCPIP, with elevated redox stress. Small interfering RNA knockdown of MCPIP restored the endothelial NO synthase-derived NO bioavailability. Administering simvastatin to CIA mice ameliorated the endothelial dysfunction, with attendant decreased aortic level of MCPIP. The beneficial effect of the statin was mediated by inhibiting nuclear factor κB binding to the MCPIP gene enhancer. CONCLUSIONS: Increased MCPIP is found in rheumatoid arthritis leading to endothelial dysfunction. Statin treatment or MCP-1 neutralizing antibody administration antagonizes MCPIP expression, thereby attenuating the endothelial dysfunction.


Assuntos
Artrite Experimental/genética , Artrite Reumatoide/genética , Células Endoteliais/patologia , Ribonucleases/genética , Animais , Artrite Experimental/metabolismo , Artrite Experimental/fisiopatologia , Artrite Reumatoide/metabolismo , Artrite Reumatoide/fisiopatologia , Aterosclerose/metabolismo , Aterosclerose/fisiopatologia , Biomarcadores/metabolismo , Células Cultivadas , Quimiocina CCL2/metabolismo , Modelos Animais de Doenças , Regulação para Baixo , Células Endoteliais/metabolismo , Regulação da Expressão Gênica , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacologia , Camundongos , Camundongos Endogâmicos , Óxido Nítrico Sintase/metabolismo , Distribuição Aleatória , Análise de Regressão , Ribonucleases/efeitos dos fármacos
8.
Phytopathology ; 103(2): 135-45, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-23095467

RESUMO

Bambusa pervariabilis × Dendrocalamopisis grandis blight is caused by a toxin produced by the fungus Arthrinium phaeospermum. In this study, a toxin fraction (P1-2-2) with an estimated molecular mass of 31 kDa was purified from a culture filtrate of this fungus by ammonium sulfate precipitation, Sephadex G-50 gel chromatography, Q Sepharose Fast Flow anion exchange resin, and Sephadex G-75 chromatography. The N-terminal amino acid sequence (i.e., H(2)N-Gln-Val-Arg-Asp-Arg-Leu-Glu-Ser-Thr) determined by Edman degradation showed homology to known serine alkaline proteases. The purified protein was named AP-toxin. Effects of the purified protein toxin on total phenol, flavonoid, total nucleic acid, DNA, RNA, soluble protein, and soluble sugar content, as well as DNase and RNase activities and disease index, were analyzed in different bamboo varieties by the impregnation method. The toxin had a significant effect on each parameter tested. In addition, a significant correlation was observed among the metabolic index, treatment time, bamboo resistance, and disease index. These data suggest that AP-toxin plays an important role in mediating the phytotoxic activities of A. phaeospermum. This study also indicates that metabolic indices could reflect the resistance indices of hybrid bamboo to blight.


Assuntos
Ascomicetos/química , Bambusa/efeitos dos fármacos , Micotoxinas/farmacologia , Doenças das Plantas/microbiologia , Bambusa/imunologia , Bambusa/metabolismo , Bambusa/microbiologia , Carboidratos/análise , Desoxirribonucleases/efeitos dos fármacos , Resistência à Doença , Flavonoides/análise , Proteínas Fúngicas/isolamento & purificação , Proteínas Fúngicas/farmacologia , Peso Molecular , Micotoxinas/isolamento & purificação , Ácidos Nucleicos/análise , Ácidos Nucleicos/efeitos dos fármacos , Fenóis/análise , Folhas de Planta/efeitos dos fármacos , Folhas de Planta/imunologia , Folhas de Planta/metabolismo , Folhas de Planta/microbiologia , Proteínas de Plantas/análise , Proteínas de Plantas/efeitos dos fármacos , Brotos de Planta/efeitos dos fármacos , Brotos de Planta/imunologia , Brotos de Planta/metabolismo , Brotos de Planta/microbiologia , Ribonucleases/efeitos dos fármacos , Análise de Sequência de Proteína
9.
Inorg Chem ; 47(24): 11965-71, 2008 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-19053337

RESUMO

We have prepared cyclic peptide nucleic acids (PNAs). These compounds do not bind complementary nucleic acids. One carboxylic ester group was introduced in the backbone of the cyclic PNAs. This group is cleaved in the presence of Cu(2+) or coordinatively unsaturated Cu(2+) complexes. The cleavage products are linear PNAs. In contrast to the cyclic PNAs, they are efficient nucleic acid binders. The rate of formation of the linear PNAs is proportional to the concentration of the cleaving agents. Therefore, one may apply highly sensitive methods of detection of linear PNAs for determination of Cu(2+) concentration. In particular, we have demonstrated that both fluorescent spectroscopy in combination with molecular beacons and MALDI-TOF mass spectrometry are suitable for the detection of Cu(2+). A range of related divalent metal ions and Eu(3+), Ln(3+), Pr(3+), Ce(3+), and Zr(4+) do not interfere with Cu(2+) detection.


Assuntos
Cobre/farmacologia , Ácidos Nucleicos Peptídicos/química , Peptídeos Cíclicos/química , Trifosfato de Adenosina/química , Cátions Bivalentes/química , Cátions Bivalentes/farmacologia , Cromatografia Líquida de Alta Pressão , DNA/química , Desoxirribonucleases/efeitos dos fármacos , Desoxirribonucleases/metabolismo , Modelos Moleculares , Conformação Molecular , Hibridização de Ácido Nucleico , Ácidos Nucleicos Peptídicos/efeitos dos fármacos , RNA/química , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo , Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos
10.
PLoS One ; 3(6): e2434, 2008 Jun 18.
Artigo em Inglês | MEDLINE | ID: mdl-18560598

RESUMO

BACKGROUND: RNases are currently studied as non-mutagenic alternatives to the harmful DNA-damaging anticancer drugs commonly used in clinical practice. Many mammalian RNases are not potent toxins due to the strong inhibition by ribonuclease inhibitor (RI) presented in the cytoplasm of mammalian cells. METHODOLOGY/PRINCIPAL FINDINGS: In search of new effective anticancer RNases we studied the effects of barnase, a ribonuclease from Bacillus amyloliquefaciens, on human cancer cells. We found that barnase is resistant to RI. In MTT cell viability assay, barnase was cytotoxic to human carcinoma cell lines with half-inhibitory concentrations (IC(50)) ranging from 0.2 to 13 microM and to leukemia cell lines with IC(50) values ranging from 2.4 to 82 microM. Also, we characterized the cytotoxic effects of barnase-based immunoRNase scFv 4D5-dibarnase, which consists of two barnase molecules serially fused to the single-chain variable fragment (scFv) of humanized antibody 4D5 that recognizes the extracellular domain of cancer marker HER2. The scFv 4D5-dibarnase specifically bound to HER2-positive cells and was internalized via receptor-mediated endocytosis. The intracellular localization of internalized scFv 4D5-dibarnase was determined by electronic microscopy. The cytotoxic effect of scFv 4D5-dibarnase on HER2-positive human ovarian carcinoma SKOV-3 cells (IC(50) = 1.8 nM) was three orders of magnitude greater than that of barnase alone. Both barnase and scFv 4D5-dibarnase induced apoptosis in SKOV-3 cells accompanied by internucleosomal chromatin fragmentation, membrane blebbing, the appearance of phosphatidylserine on the outer leaflet of the plasma membrane, and the activation of caspase-3. CONCLUSIONS/SIGNIFICANCE: These results demonstrate that barnase is a potent toxic agent for targeting to cancer cells.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Ribonucleases/efeitos dos fármacos , Proteínas de Bactérias , Linhagem Celular Tumoral , Feminino , Humanos , Microscopia Eletrônica , RNA Neoplásico/metabolismo , Ribonucleases/metabolismo
11.
Int J Oncol ; 30(4): 841-7, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17332922

RESUMO

Onconase (ONC), (ranpirnase) a cytotoxic ribonuclease isolated from amphibian oocytes and early embryos targeting tumor cells in vitro and in vivo, is currently in a confirmatory Phase IIIb clinical trial for unresectable malignant mesothelioma where it demonstrates antitumor activity with relatively minor overall toxicity to patients. Since hyperthermia has been shown to be synergistic with certain antitumor modalities, the aim of the present study was to explore whether the cytotoxic effects of ONC can be enhanced under conditions of mild hyperthermia. Treatment of human lymphoblastoid TK6 cells with 2 or 5 microg/ml of ONC at 40 degrees C for 24 or 48 h led to 64-200% enhancement in incidence of apoptosis assessed by frequency of cells showing the presence of activated (cleaved) caspase-3 or activated serine proteases, compared to treatment at 37.5 degrees C. The incidence of apoptosis at 40 degrees C in the absence of ONC was unchanged compared to 37.5 degrees C, for up to 48 h. Although at 41 degrees C in absence of ONC the incidence of apoptosis was elevated compared to 37 degrees C the cytotoxicity of ONC was further enhanced and the overall pro-apoptotic effect was above the level of additive effects of ONC plus that of 41 degrees C-hyperthermia. While the mechanism of the observed enhancement of ONC cytotoxicity is currently under investigation, the findings suggest that a combination of ONC and mild hyperthermia should be explored to increase effectiveness of ONC in cancer treatment.


Assuntos
Hipertermia Induzida , Leucemia de Células B/terapia , Ribonucleases/efeitos dos fármacos , Apoptose , Caspase 3/análise , Caspase 3/metabolismo , Terapia Combinada , Humanos , Leucemia de Células B/tratamento farmacológico , Leucemia de Células B/patologia , Serina Endopeptidases/análise , Serina Endopeptidases/metabolismo , Células Tumorais Cultivadas
12.
J Mol Cell Cardiol ; 41(1): 160-9, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16720030

RESUMO

Platelet-derived growth factor (PDGF) has protean manifestations, including the regulation of growth and migration, in many cell types. We have previously reported that PDGF-BB induces the accumulation of monocyte chemoattractant protein (MCP)-1 mRNA in smooth muscle cells (SMC), in large part due to an increase in mRNA stability. To elucidate the mechanism by which PDGF-BB stabilizes MCP-1 mRNA, we have employed in vitro RNA gel mobility shift and decay assays. Cytoplasmic extracts from PDGF-BB-treated SMC increased the half-life of in vitro transcribed MCP-1 mRNA from approximately 45 min to >2 h. PDGF-BB-inhibitable degradation was not dependent on specific regions of the MCP-1 mRNA and was equally effective on a variety of in vitro transcribed mRNAs. Angiotensin II had a similar effect on MCP-1 mRNA stability, whereas tumor necrosis factor-alpha and basic fibroblast growth factor did not. The PDGF-BB-inhibitable RNAse activity was active at pH 6.6 and heat stable, but was sensitive to proteinase K. Extracts from PDGF-BB- or angiotensin II-treated cells inhibited the RNAse activity of control extracts, suggesting that the effect of PDGF-BB and angiotensin II are due to activation of a soluble inhibitor of the RNAse. The effect of PDGF-BB was blocked by inhibitors of tyrosine phosphorylation, but not by inhibitors of phosphatidylinositol 3-kinase or mitogen-activated protein kinases. These studies provide new insights into the mechanisms by which PDGF-BB enhances mRNA accumulation.


Assuntos
Quimiocina CCL2/genética , Músculo Liso Vascular/efeitos dos fármacos , Fator de Crescimento Derivado de Plaquetas/farmacologia , Estabilidade de RNA/efeitos dos fármacos , Ribonucleases/metabolismo , Angiotensina II/farmacologia , Animais , Becaplermina , Células Cultivadas , Quimiocina CCL2/efeitos dos fármacos , Classe Ib de Fosfatidilinositol 3-Quinase , Regulação para Baixo , Inibidores Enzimáticos/farmacologia , Meia-Vida , Isoenzimas/metabolismo , Masculino , Proteínas Quinases Ativadas por Mitógeno/antagonistas & inibidores , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Músculo Liso Vascular/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Fator de Crescimento Derivado de Plaquetas/metabolismo , Proteína Quinase C/antagonistas & inibidores , Proteína Quinase C/metabolismo , Proteínas Proto-Oncogênicas c-sis , RNA Mensageiro/efeitos dos fármacos , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores do Fator de Crescimento Derivado de Plaquetas/metabolismo , Ribonucleases/efeitos dos fármacos , Quinases da Família src/antagonistas & inibidores , Quinases da Família src/metabolismo
13.
Protein Sci ; 14(9): 2344-9, 2005 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16081652

RESUMO

Perchloric acid-soluble protein (PSP) is highly conserved during evolution from bacteria to mammals. Although PSP has been recognized as an inhibitor of translation and proliferation in vitro, its precise biological role has not yet been elucidated. Since we previously found similar distributions for PSP and the endoplasmic reticulum (ER) and Golgi complex, the intracellular distribution of PSP was analyzed in more detail. Immunofluorescence studies indicated that PSP co-localized with the ER and Golgi complex, since the distribution pattern of PSP was well matched to both of these organelles. An immunoelectron microscopic study revealed PSP was located not only in the cytosol but also on the surface of the outer ER membrane. Since PSP was present on the ER, we speculated that it may be associated with ER function. Therefore, we analyzed whether or not the ER stress response, which is one of the ER functions, affected PSP expression. The results showed that various ER stressors (thapsigargin, A23187, tunicamycin, brefeldin A, and cisplatin) provoked a dramatic change in the localization of PSP from outside of the nucleus to inside the nucleus within 3 h. Moreover, the ER stressors induced PSP expression. These results suggest that PSP is involved in the cellular response to ER stressors, and that the change in localization of PSP from the ER to the nucleus may be associated with ER stress responses.


Assuntos
Retículo Endoplasmático/efeitos dos fármacos , Retículo Endoplasmático/metabolismo , Proteínas de Choque Térmico/metabolismo , Ribonucleases/metabolismo , Transporte Ativo do Núcleo Celular , Animais , Brefeldina A/farmacologia , Calcimicina/farmacologia , Núcleo Celular/efeitos dos fármacos , Núcleo Celular/metabolismo , Cisplatino/farmacologia , Complexo de Golgi/metabolismo , Proteínas de Choque Térmico/efeitos dos fármacos , Membranas Intracelulares/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , Ribonucleases/efeitos dos fármacos , Tapsigargina/farmacologia , Tunicamicina/farmacologia
14.
J Inorg Biochem ; 99(7): 1490-6, 2005 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-15919117

RESUMO

Three copper(II) complexes of aminoquinoline derivatives, l-glycine-N'-8-quinolylamide (L1), l-alanine-N'-8-quinolylamide (L2), and N-(8-quinolyl) pyridine-2-carboxamide (L3) have been shown to cleave plasmid DNA pBR322 and pUC18 with or without the presence of H(2)O(2)/ascorbate. Crystallographic data reveal that the Cu(II) coordination plane in [Cu(L1)(Ac)(H(2)O)] (1) and [Cu(L2)(Ac)] (2) is nearly co-planar with the quinoline ring. The cleavage activity follows the order of complex 1>complex 2>complex 3, which is in agreement with the reverse order of the steric hindrance of the amino-substituent of the ligands. The presence of the standard radical scavengers does not have a clear effect on the cleavage efficiency of the Cu(II) complexes, suggesting the reactive species leading to DNA damage could be DNA-bound copper-centered radicals rather than the free diffusible ones.


Assuntos
Aminoquinolinas/química , Cobre/química , Compostos Organometálicos/química , Ribonucleases/efeitos dos fármacos , Cristalografia por Raios X , DNA/química , Dano ao DNA , Sequestradores de Radicais Livres/química , Modelos Moleculares , Conformação Molecular , Plasmídeos/efeitos dos fármacos , Ribonucleases/química
15.
Int Arch Allergy Immunol ; 134(2): 141-9, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15153794

RESUMO

BACKGROUND: Eosinophils play an important role in the pathogenesis of allergic diseases. Sensitization and exposure to cockroach allergen have been demonstrated to be one of the major risk factors for the development of bronchial asthma. However, little is known regarding the functional capacity of cockroach extract antigen to activate human eosinophils. OBJECTIVE: We investigated whether German cockroach extract can activate human eosinophils to release cytotoxic inflammatory mediators. METHODS: Purified eosinophils from the peripheral blood were incubated with various concentrations (0-200 microg/ml) of German cockroach extract antigen. Effector functions of eosinophils were checked by degranulation and superoxide anion production. In addition, we examined surface expression of CD11b and CD69, and intracellular activation of p38 mitogen-activated protein kinase (p38 MAP kinase) in cockroach-stimulated eosinophils. RESULTS: German cockroach extract induced degranulation and superoxide production from human eosinophils. In addition, incubation of eosinophils for 3 h with the cockroach extract resulted in an increased level of the surface expression of CD11b and CD69. Furthermore, cockroach-induced superoxide production from eosinophils was significantly inhibited by the pretreatment of cells with a p38 MAP kinase inhibitor SB202190. Indeed, a large amount of phosphorylated forms of p38 MAP kinase was detected in cockroach-stimulated eosinophils. CONCLUSIONS: Our results suggest that German cockroach extract induces activation of human eosinophils to release cytotoxic inflammatory mediators such as superoxide and granular proteins.


Assuntos
Alérgenos/farmacologia , Baratas , Eosinófilos/efeitos dos fármacos , Eosinófilos/fisiologia , Mediadores da Inflamação/metabolismo , Alérgenos/administração & dosagem , Animais , Antígenos de Diferenciação/biossíntese , Antígenos de Diferenciação/efeitos dos fármacos , Degranulação Celular/efeitos dos fármacos , Citotoxicidade Imunológica/efeitos dos fármacos , Relação Dose-Resposta a Droga , Ativação Enzimática/efeitos dos fármacos , Neurotoxina Derivada de Eosinófilo , Eosinófilos/metabolismo , Exocitose/efeitos dos fármacos , Humanos , Interleucina-5/administração & dosagem , Proteínas Quinases Ativadas por Mitógeno/efeitos dos fármacos , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Fosforilação/efeitos dos fármacos , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo , Transdução de Sinais/efeitos dos fármacos , Superóxidos/metabolismo , Proteínas Quinases p38 Ativadas por Mitógeno
16.
Pediatr Allergy Immunol ; 14(5): 394-400, 2003 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-14641610

RESUMO

Regular anti-inflammatory treatment is essential in treating persistent asthma. Most commonly, inhaled corticosteroids (ICS) are used. However, especially in children, there is concern about the long-term safety of ICS such that doses should be kept to a minimum. The use of theophylline has decreased because of frequent side-effects in therapeutic doses. In adults, there have been reports about an immunomodulatory effect of low-dose theophylline. To study the clinical and immunomodulatory effect in children, 36 patients (mean age 12.5 SD 2.4 years) with moderate, persistent asthma on regular ICS were recruited into a placebo-controlled, double-blind study. After a 6-week run-in period, patients received either theophylline 10 mg/kg bodyweight or placebo for 12 weeks. Diary cards, lung function, peripheral blood lymphocyte subpopulations and serum eosinophil cationic protein (sECP) were assessed. In the treatment group, mean serum theophylline was 7.1 mg/l. There was no change in symptoms or use of rescue medication. Mean (SD) peak expiratory flow (PEF) increased from 86% (24) to 95% (18) predicted. sECP decreased from 43.2 microg/l (32.5) to 26.5 microg/l (16.9) (p = 0.02). Lymphocyte subpopulations did not change. The study failed to show a beneficial clinical or an immunomodulatory effect of theophylline when used in low doses. These results do not support a more important role of theophylline in the long-term treatment of moderate childhood asthma.


Assuntos
Broncodilatadores/administração & dosagem , Teofilina/administração & dosagem , Administração por Inalação , Adolescente , Corticosteroides/administração & dosagem , Resistência das Vias Respiratórias/efeitos dos fármacos , Androstadienos/administração & dosagem , Antígenos de Diferenciação de Linfócitos T/sangue , Antígenos de Diferenciação de Linfócitos T/efeitos dos fármacos , Asma/sangue , Asma/tratamento farmacológico , Asma/fisiopatologia , Biomarcadores/sangue , Proteínas Sanguíneas/efeitos dos fármacos , Broncodilatadores/sangue , Budesonida/administração & dosagem , Criança , Proteção da Criança , Relação Dose-Resposta a Droga , Método Duplo-Cego , Proteínas Granulares de Eosinófilos , Feminino , Fluticasona , Volume Expiratório Forçado/efeitos dos fármacos , Alemanha , Humanos , Contagem de Linfócitos , Subpopulações de Linfócitos/efeitos dos fármacos , Masculino , Pico do Fluxo Expiratório/efeitos dos fármacos , Valor Preditivo dos Testes , Testes de Função Respiratória , Ribonucleases/sangue , Ribonucleases/efeitos dos fármacos , Serviços de Saúde Escolar , Linfócitos T/efeitos dos fármacos , Teofilina/sangue , Tempo , Resultado do Tratamento , Capacidade Vital/efeitos dos fármacos
17.
Allergy ; 58(7): 602-7, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12823118

RESUMO

BACKGROUND: Noninvasive surrogate markers provide valuable information on the asthmatic inflammatory process. We wished to examine the effects of low dose fluticasone/salmeterol combination on different commonly used inflammatory markers in moderate persistent asthma. METHODS: Twenty-five moderate persistent atopic asthmatics were enrolled of whom 20 completed an open label study. Following an initial 4 week steroid washout period in which patients took salmeterol 50 microg dry powder inhaler 1 puff BD, they received the addition of fluticasone as fluticasone 100 microg/salmeterol 50 microg combination dry powder inhaler 1 puff BD for the next 2 weeks. Exhaled nitric oxide, spirometry, methacholine PD20, sputum/blood eosinophils and sputum/serum eosinophil cationic protein (ECP) were measured following the salmeterol only and fluticasone/salmeterol combination treatment periods. RESULTS: Compared to salmeterol alone (i.e. after the steroid washout), the use of fluticasone/salmeterol combination conferred significant improvements (P < 0.05) in all surrogate markers of inflammation apart from serum ECP. Geometric mean fold changes were 4.3-fold/1.3-fold for sputum/blood eosinophils, 2.2-fold/1.2-fold for sputum/serum ECP, 2.3-fold for methacholine PD20 and 1.8-fold for exhaled nitric oxide. CONCLUSIONS: Surrogate markers apart from serum ECP may be used as a guide to evaluate the anti-inflammatory effects of low dose inhaled corticosteroids. Sputum markers tend to be more sensitive than blood when assessing the anti-inflammatory response.


Assuntos
Albuterol/análogos & derivados , Albuterol/administração & dosagem , Androstadienos/administração & dosagem , Antiasmáticos/administração & dosagem , Asma/tratamento farmacológico , Broncodilatadores/administração & dosagem , Administração por Inalação , Adolescente , Adulto , Idoso , Asma/metabolismo , Beclometasona/administração & dosagem , Biomarcadores/análise , Proteínas Sanguíneas/efeitos dos fármacos , Proteínas Sanguíneas/metabolismo , Testes de Provocação Brônquica , Broncoconstritores/administração & dosagem , Budesonida/administração & dosagem , Clorofluorcarbonetos/administração & dosagem , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Proteínas Granulares de Eosinófilos , Eosinófilos/efeitos dos fármacos , Eosinófilos/metabolismo , Fluticasona , Fluxo Expiratório Forçado/efeitos dos fármacos , Volume Expiratório Forçado/efeitos dos fármacos , Humanos , Cloreto de Metacolina/administração & dosagem , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo , Xinafoato de Salmeterol , Índice de Gravidade de Doença , Espirometria , Escarro/química , Escarro/metabolismo , Resultado do Tratamento
18.
Allergy ; 58(5): 397-406, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12752326

RESUMO

BACKGROUND: The aim of this study was to investigate the effects of ketotifen on different parameters of human eosinophil functions, namely chemotaxis, oxidative metabolism and mediator release, induced after activation. METHODS: Eosinophils from hypereosinophilic patients or normal donors were purified by Percoll gradient and the magnetic cell separation system. Chemotaxis was studied using the Boyden chamber technique using three potent chemoattractants: formyl-methionine-leucine-phenylalanine (fMLP), interleukin (IL)-5 and eotaxin. Oxidative metabolism was determined by a luminol-dependent chemiluminescence assay after activation with eotaxin or secretory immunoglobulin A (sIgA). The release of eosinophil cationic protein (ECP) and eosinophil derived neurotoxin (EDN) was measured by radioimmunoassay after activation with sIgA. RESULTS: At pharmacologically active concentrations and in a dose-dependent manner, ketotifen significantly inhibited the chemotaxis of eosinophils to fMLP, IL-5 and eotaxin. The production of reactive oxygen species induced by eotaxin and sIgA was decreased by ketotifen, showing a more pronounced effect when cells were activated by eotaxin. Activation by sIgA resulted in ECP and EDN release, which was partially inhibited by ketotifen. CONCLUSIONS: Through inhibition of chemotaxis, ketotifen might limit the number of eosinophils at the inflammation site during allergic reaction. Furthermore, inhibition by ketotifen of main inflammatory mediators release suggests a potential role of the drug in limiting the pathological potential of eosinophils.


Assuntos
Antialérgicos/farmacologia , Quimiotaxia de Leucócito/efeitos dos fármacos , Eosinófilos/efeitos dos fármacos , Cetotifeno/farmacologia , Proteínas Sanguíneas/efeitos dos fármacos , Estudos de Casos e Controles , Sobrevivência Celular/efeitos dos fármacos , Quimiocina CCL11 , Quimiocinas CC/antagonistas & inibidores , Fatores Quimiotáticos de Eosinófilos , Relação Dose-Resposta a Droga , Neurotoxina Derivada de Eosinófilo , Eosinófilos/metabolismo , Oftalmopatias/tratamento farmacológico , Humanos , Interleucina-5/antagonistas & inibidores , N-Formilmetionina Leucil-Fenilalanina/antagonistas & inibidores , Oxirredução/efeitos dos fármacos , Espécies Reativas de Oxigênio/antagonistas & inibidores , Ribonucleases/efeitos dos fármacos
19.
Phytother Res ; 16(8): 778-80, 2002 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-12458488

RESUMO

Dichloromethane, methanol and aqueous extracts from the leaves of Terminalia triflora were investigated for their inhibitory effect on polymerase and ribonuclease activities of HIV reverse transcriptase.The most potent activity was found in the aqueous extract, which inhibited both polymerase and ribonuclease activities of the enzyme with an IC50 of 1.6 micro g/mL and 1.8 micro g/mL respectively. The antiinfective activity of the extract was demonstrated in HLT4LacZ-IIIB cell culture with an IC50 of 1.0 micro g/mL. The extract was submitted to a purification process by extractive and chromatographic methods. The activity remained in the hydrophillic fraction. Tannins present in this active purified fraction, as determined by TLC and HPLC methods, could account for the anti HIV-RT activity found in the aqueous extract.


Assuntos
Fármacos Anti-HIV/farmacologia , HIV-1/efeitos dos fármacos , Fitoterapia , Extratos Vegetais/farmacologia , Inibidores da Transcriptase Reversa/farmacologia , Terminalia , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Linhagem Celular/efeitos dos fármacos , Linhagem Celular/enzimologia , Cromatografia Líquida de Alta Pressão , Relação Dose-Resposta a Droga , Infecções por HIV/tratamento farmacológico , Transcriptase Reversa do HIV/antagonistas & inibidores , HIV-1/enzimologia , Humanos , Concentração Inibidora 50 , Inibidores da Síntese de Ácido Nucleico , Extratos Vegetais/administração & dosagem , Extratos Vegetais/uso terapêutico , Folhas de Planta , Inibidores da Transcriptase Reversa/administração & dosagem , Inibidores da Transcriptase Reversa/uso terapêutico , Ribonucleases/efeitos dos fármacos
20.
Mol Cell Endocrinol ; 182(1): 129-44, 2001 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-11500246

RESUMO

20-Hydroxyecdysone induces poly(A) shortening and the subsequent degradation of transcripts encoding the larval glue protein LGP-1 in Drosophila virilis late third larval instar salivary glands. Degradation concurs with the transient increase of ribonucleolytic activities in the gland cells. In vitro nuclease assays using crude cytoplasmic extracts of ecdysone-treated salivary glands demonstrate degradation to be deadenylation-independent and that the induced ribonucleolytic activities initiate the degradation of the Lgp-1 transcripts in putative single-stranded loop regions. The independence of degradation from deadenylation is also found in vivo in transformed D. melanogaster carrying a modified Lgp-1 gene.


Assuntos
Drosophila/genética , Ecdisona/farmacologia , Estabilidade de RNA/efeitos dos fármacos , Glândulas Salivares/metabolismo , Animais , Animais Geneticamente Modificados , Técnicas de Cultura , Indução Enzimática/efeitos dos fármacos , Proteínas do Grude Salivar de Drosophila/genética , Larva/genética , Metamorfose Biológica , Modelos Moleculares , Poli A/metabolismo , RNA Mensageiro/metabolismo , Ribonucleases/efeitos dos fármacos , Ribonucleases/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...